On June 21, 2025, Eli Lilly and Company, a U.S. pharmaceutical firm, announced positive key results from the first Phase 3 ACHIEVE-1 clinical trial of its investigational oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist Orforglipron. The company plans to submit a regulatory application for the treatment of type 2 diabetes in 2026.Unlike traditional injectable GLP-1 […]